苑東生物(688513.SH):擬投建國際化標準的醫藥研發技術平台及高端化學藥製劑產業化項目
格隆匯 1 月 26日丨苑東生物(688513.SH)公佈,公司為了加快實施成為全球特異型專利處方藥醫藥企業的戰略目標,進一步提高藥品研發創新能力和速度,同時具備符合美國FDAcGMP及歐盟EU GMP標準的國際化生產製造能力,公司決定由全資子公司成都碩德藥業有限公司耗時2.5年,投資33642萬元建設國際化標準的醫藥研發技術平台和符合美國FDAcGMP及歐盟EU GMP標準的高端口服液車間、高活性高毒性注射劑車間及高端固體制劑車間。
項目建成後,公司研發技術平台將達到國際化標準,研發創新能力將進一步增強,同時具備國際化標準的生產製造能力,填補公司在國際高端口服液、高活性高毒性注射劑及高端固體制劑等領域的空白。
該項目圍繞公司主營業務展開,符合國家相關的產業政策以及公司未來整體戰略發展方向,建立國際化標準的醫藥研發技術平台和生產製造與質量管理體系,能進一步提高藥品研發創新能力和速度,同時加快高端化學藥製劑國際化,有利於提升公司綜合實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.